Skip to main content

Table 3 Comparison of patients and treated infections, according to the 1st Cmax observed (on D1)

From: Amikacin pharmacokinetic/pharmacodynamic in intensive care unit: a prospective database

Patients dataa

Cmax on D1

p

< 64 mg/L

≥ 64 mg/L

(n = 56)

(n = 37)

Female

20 (35.7)

17 (45.9)

0.32

Age (years)

60 [24–90]

66 [46–88]

0.038

BMI admission

24.5 [15–42.4]

25.4 [18.8–45.1]

0.17

SAPS 2 admission

51.5 [15–105]

54 [29–124]

0.38

Chronic renal failure

7 (12.5)

10 (27)

0.10

Data on D1

(n = 60)

(n = 38)

 

Admission time—D1 (d)

5 [1–71]

4 [1–35]

0.25

Weight (kg)

75.5 [45–130]

79.5 [48–120]

0.15

Weight gain/admission (kg)

0 [− 15–25]

0 [− 12–23]

0.26

SOFA

6.5 [0–17]

8 [0–15]

0.17

Mechanical ventilation

41 (68.3)

21 (55.2)

0.19

Vasopressor support

32 (53.3)

26 (68.4)

0.14

Renal replacement therapy

2 (3.3)

3 (7.9)

0.37

Urine 24 h volume (mL)

1100 [0–5300]

1225 [0–4900]

0.52

Serum creatinine (µmol/L)

58.5 [23–453]

132 [31–609]

0.0003

24-h fluid intake (mL)

3200 [1000–12,642]

2868 [1000–11,000]

0.90

Dose administered per kg (mg)

25 [15.6–31.8]

25 [20.3–31.3]

0.11

Total dose administered (mg)

1800 [1000–3250]

2000 [1250–3000]

0.034

  1. Data expressed in n (%) or median [min–max]
  2. aComparison according to the Cmax measured during the first episode of infection treated with amikacin